Cited by 353Pancreatic and Hepatic Oncology ResearchBreast Cancer Treatment StudiesCholangiocarcinoma and Gallbladder Cancer Studies

The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer

Open access

O’Kane, Grainne M., Grünwald, Barbara T., Jang, Gun-Ho, Masoomian, Mehdi, Picardo, Sarah, Grant, Robert C., Denroche, Robert E., Zhang, Amy, Wang, Yifan, Miller, Jessica K., Lam, Bernard, Krzyzanowski, Paul M., Lungu, Ilinca M., Bartlett, John M.S., Peralta, Melanie, Vyas, Foram, Khokha, Rama, Biagi, James, Chadwick, Dianne, Ramotar, Stephanie, Hutchinson, Shawn, Dodd, Anna, Wilson, Julie M., Notta, Faiyaz, Zogopoulos, George, Gallinger, Steven, Knox, Jennifer J., Fischer, Sandra E.·2020·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-19-3724

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: To determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) and to explore GATA6 expression as a surrogate biomarker. Experimental Design: Within the COMPASS trial, patients proceeding to chemotherapy for advanced PDAC undergo tumor biopsy for RNA-sequencing (RNA-seq). Overall response rate (ORR) and overall survival (OS) were stratified by subtypes and according to chemotherapy received. Correlation of GATA6 with the subtypes using gene expression profiling, in situ hybridization (ISH) was explored. Results: Between December 2015 and May 2019, 195 patients (95%) had enough tissue for RNA-seq; 39 (20%) were classified as basal-like and 156 (80%) as classical. RECIST response data were available for 157 patients; 29 basal-like and 128 classical where the ORR was 10% versus 33%, respectively (P = 0.02). In patients with basal-like tumors treated with modified FOLFIRINOX (n = 22), the progression rate was 60% compared with 15% in classical PDAC (P = 0.0002). Median OS in the intention-to-treat population (n = 195) was 9.3 months for classical versus 5.9 months for basal-like PDAC (HR, 0.47; 95% confidence interval, 0.32–0.69; P = 0.0001). GATA6 expression by RNA-seq highly correlated with the classifier (P < 0.001) and ISH predicted the subtypes with sensitivity of 89% and specificity of 83%. In a multivariate analysis, GATA6 expression was prognostic (P = 0.02). In exploratory analyses, basal-like tumors, could be identified by keratin 5, were more hypoxic and enriched for a T-cell–inflamed gene expression signature. Conclusions: The basal-like subtype is chemoresistant and can be distinguished from classical PDAC by GATA6 expression. See related commentary by Collisson, p. 4715

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-3724

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Cancer statistics, 2016
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
The control of the false discovery rate in multiple testing under dependency
Benjamini, Y., & Yekutieli, D. (2001) · The Annals of Statistics · doi:10.1214/aos/1013699998 · Cited by 10,490
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712

Show all 39 references

Sorted by citations

Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
Raghavan, S., Winter, P. S., Navia, A. W., Williams, H. L., DenAdel, A., Lowder, K. E., Galvez-Reyes, J., Kalekar, R. L., Mulugeta, N., Kapner, K. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.017 · Cited by 592
Proteogenomic characterization of pancreatic ductal adenocarcinoma
Cao, L., Huang, C., Cui Zhou, D., Hu, Y., Lih, T. M., Savage, S. R., Krug, K., Clark, D. J., Schnaubelt, M., Chen, L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.023 · Cited by 578
Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance
Sherman, M. H., & Beatty, G. L. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031621-024600 · Cited by 501
Spatially confined sub-tumor microenvironments in pancreatic cancer
Grünwald, B. T., Devisme, A., Andrieux, G., Vyas, F., Aliar, K., McCloskey, C. W., Macklin, A., Jang, G. H., Denroche, R., Romero, J. M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.022 · Cited by 433
Self-citation
Therapeutic developments in pancreatic cancer
Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 438
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
Connor, A. A., & Gallinger, S. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00418-1 · Cited by 369
Self-citation
Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment
Werba, G., Weissinger, D., Kawaler, E. A., Zhao, E., Kalfakakou, D., Dhara, S., Wang, L., Lim, H. B., Oh, G., Jing, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36296-4 · Cited by 303
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“Patient data suggest that the classical subtype of PDAC responds better to chemotherapy than the poorly prognostic basal-like PDAC subtype (44, 58, 59).”
Background
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 255
The pancreatic cancer genome revisited
Hayashi, A., Hong, J., & Iacobuzio-Donahue, C. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00463-z · Cited by 211
The biological underpinnings of therapeutic resistance in pancreatic cancerPreprint
Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 139
Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Grossman, J. E., Muthuswamy, L. B., Huang, L., Akshinthala, D., Perea, S., González, R. S., Tsai, L. L., Cohen, J., Bockorny, B., Bullock, A. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4116 · Cited by 128
Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes
Miyabayashi, K., Baker, L. A., Deschênes, A., Traub, B., Caligiuri, G., Plenker, D., Alagesan, B., Belleau, P., Li, S., Kendall, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0133 · Cited by 124
Self-citation
QuPath: The global impact of an open source digital pathology system
Humphries, M. P., Maxwell, P., & Salto‐Tellez, M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.022 · Cited by 133
Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer
Yousuf, S., Qiu, M., von Voithenberg, L. V., Hulkkonen, J., Mačinković, I., Schulz, A. R., Hartmann, D., Mueller, F., Mijatovic, M., Ibberson, D., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.036 · Cited by 124
Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer
Pei, G., Min, J., Rajapakshe, K., Branchi, V., Liu, Y., Selvanesan, B. C., Thege, F. I., Sadeghian, D., Zhang, D., Cho, K. S., et al. (2025) · Nature · doi:10.1038/s41586-025-08927-x · Cited by 121
Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression
Ruivo, C. F., Bastos, N., Adem, B., Batista, I. A., Durães, C., Melo, C. A., Castaldo, S. A., Campos-Laborie, F. J., Moutinho-Ribeiro, P., Morão, B., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324994 · Cited by 102
Consensus, debate, and prospective on pancreatic cancer treatments
Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 104
Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular Subtypes
Leiphrakpam, P. D., Chowdhury, S., Zhang, M. H., Bajaj, V., Dhir, M., & Are, C. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01183-2 · Cited by 99
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
Nicolle, R., Gayet, O., Duconseil, P., Vanbrugghe, C., Roques, J., Bigonnet, M., Blum, Y., Elarouci, N., Armenoult, L., Ayadi, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.601 · Cited by 97
IL-17A-producing CD8 + T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts
Picard, F. S. R., Lutz, V., Brichkina, A. I., Neuhaus, F., Ruckenbrod, T., Hupfer, A., Raifer, H., Klein, M., Bopp, T., Pfefferle, P. I., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327855 · Cited by 88
A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Singhal, A., Styers, H. C., Rub, J., Li, Z., Torborg, S. R., Kim, J. Y., Grbovic-Huezo, O., Feng, H., Tarcan, Z. C., Sahin Ozkan, H., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0740 · Cited by 84
A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS
Duan, X., Zhang, T., Feng, L., de Silva, N., Greenspun, B. C., Wang, X., Moyer, J. E., Martin, M. L., Chandwani, R., Elemento, O., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.11.011 · Cited by 85
Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer
Li, Y., Tang, S., Shi, X., Lv, J., Wu, X., Zhang, Y., Wang, H., He, J., Zhu, Y., Ju, Y., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101162 · Cited by 79
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 90
Clinical Impact of Molecular Subtyping of Pancreatic Cancer
Zhou, X., Hu, K., Bailey, P. J., Springfeld, C., Roth, S., Kurilov, R., Brors, B., Gress, T. M., Buchholz, M., An, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.743908 · Cited by 84
EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6
Patil, S., Steuber, B., Kopp, W., Kari, V., Urbach, L., Wang, X., Küffer, S., Bohnenberger, H., Spyropoulou, D., Zhang, Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0672 · Cited by 79
Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma
Saillard, C., Delecourt, F., Schmauch, B., Moindrot, O., Svrcek, M., Bardier–Dupas, A., Emile, J., Ayadi, M., Rebours, V., de Mestier, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39026-y · Cited by 74
Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy
Qiang, L., Hoffman, M. T., Ali, L. R., Castillo, J. I., Kageler, L., Temesgen, A., Lenehan, P., Wang, S. J., Bello, E., Cardot-Ruffino, V., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.038 · Cited by 75
Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with poor prognosis
Kim, S., Leem, G., Choi, J., Koh, Y., Lee, S., Nam, S., Kim, J. S., Park, C. H., Hwang, H. K., Min, K. I., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01287-7 · Cited by 81
Mechanisms of PDAC subtype heterogeneity and therapy response
Espinet, E., Klein, L., Puré, E., & Singh, S. K. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.08.005 · Cited by 70
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response
Law, H. C.-H., Lagundžin, D., Clement, E. J., Qiao, F., Wagner, Z. S., Krieger, K. L., Costanzo-Garvey, D. L., Caffrey, T. C., Grem, J. L., DiMaio, D. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1496 · Cited by 71
Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine
Casolino, R., Braconi, C., Malleo, G., Paiella, S., Bassi, C., Milella, M., Dreyer, S. B., Froeling, F. E. M., Chang, D. K.-F., Biankin, A. V., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.013 · Cited by 68
APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis
Wörmann, S. M., Zhang, A. X. W., Thege, F. I., Cowan, R. W., Rupani, D. N., Wang, R., Manning, S. L., Gates, C., Wu, W.-S., Levin-Klein, R., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00268-8 · Cited by 69
Self-citation
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Zhou, X., An, J., Kurilov, R., Brors, B., Hu, K., Peccerella, T., Roessler, S. K., Pfütze, K., Schulz, A., Wolf, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00628-6 · Cited by 68
Improving outcomes of patients with pancreatic cancer
Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 71
A Prospective Feasibility Trial to Challenge Patient–Derived Pancreatic Cancer Organoids in Predicting Treatment Response
Beutel, A. K., Schütte, L. D., Scheible, J., Roger, É., Müller, M., Perkhofer, L., Kestler, A. M. T. U., Kraus, J. M., Kestler, H. A., Barth, T. F. E., et al. (2021) · Cancers · doi:10.3390/cancers13112539 · Cited by 67
Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of the Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential
Sans, M., Makino, Y., Min, J., Rajapakshe, K., Yip-Schneider, M., Schmidt, C. M., Hurd, M. W., Burks, J. K., Gomez, J. A., Thege, F. I., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1200 · Cited by 64
Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma
Chijimatsu, R., Kobayashi, S., Takeda, Y., Kitakaze, M., Tatekawa, S., Arao, Y., Nakayama, M., Tachibana, N., Saito, T., Ennishi, D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104659 · Cited by 65
Overcoming therapy resistance in pancreatic cancer: New insights and future directions
Espona‐Fiedler, M., Patthey, C., Lindblad, S., Sarró, I., & Öhlund, D. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116492 · Cited by 62
Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics
Topham, J. T., Karasinska, J. M., Lee, M. K. C., Csizmók, V., Williamson, L., Jang, G. H., Denroche, R. E., Tsang, E. S., Kalloger, S. E., Wong, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2831 · Cited by 54
Self-citation
PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer
Rademaker, G., Hernandez, G. A., Seo, Y., Dahal, S., Miller‐Phillips, L., Li, A. L., Peng, X. L., Luan, C., Qiu, L., Liegeois, M. A., et al. (2025) · Nature · doi:10.1038/s41586-025-09017-8 · Cited by 65
Molecular Subtyping and Precision Medicine for Pancreatic Cancer
Froeling, F. E. M., Casolino, R., Pea, A., Biankin, A. V., Chang, D. K.-F., & Precision-Panc, O. B. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010149 · Cited by 52
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA –Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Stossel, C., Raitses‐Gurevich, M., Atias, D., Beller, T., Gorman, Y. G., Halperin, S., Peer, E., Denroche, R. E., Zhang, A. X. W., Notta, F., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0412 · Cited by 53
Self-citation
TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes
Eyres, M., Lanfredini, S., Xu, H., Burns, A., Blake, A., Willenbrock, F. W., Goldin, R. D., Hughes, D. L., Hughes, S. L., Thapa, A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.044 · Cited by 50
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study
Philip, P. A., Sahai, V., Bahary, N., Mahipal, A., Kasi, A., Lima, C. M. S. R., Alistar, A. T., Oberstein, P. E., Golan, T., Metges, J., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02659 · Cited by 54
The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer
Duan, K., Jang, G.-H., Grant, R. C., Wilson, J. M., Notta, F., O'Kane, G. M., Knox, J. J., Gallinger, S., & Fischer, S. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-94544-3 · Cited by 45
Self-citation
Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU)
Hosen, S. M. Z., Uddin, M. N., Xu, Z., Buckley, B. J., Perera, C. J., Pang, T., Mekapogu, A. R., Moni, M. A., Notta, F., Gallinger, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1060957 · Cited by 50
Self-citation
Next-generation therapies for pancreatic cancer
Buckley, C. W., & O'Reilly, E. M. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2322648 · Cited by 49
Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer
Klein, L., Tu, M., Krebs, N., Urbach, L., Grimm, D. T., Latif, M. U., Penz, F., Blandau, A., Wu, X., Samuel, R. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55330-7 · Cited by 51
Self-citation
Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer
Datta, J., Bianchi, A., Silva, I. D. C., Deshpande, N., Cao, L., Mehra, S., Singh, S. P., Rafie, C. I., Sun, X., Chen, X., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02368-w · Cited by 46
Self-citation
Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis in pancreatic cancer
Liu, Z., Hayashi, H., Matsumura, K., Ogata, Y., Sato, H., Shiraishi, Y., Uemura, N., Miyata, T., Higashi, T., Nakagawa, S., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02106-9 · Cited by 46
A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists
Garajová, I., Peroni, M., Gelsomino, F., & Leonardi, F. (2023) · Current Oncology · doi:10.3390/curroncol30110694 · Cited by 48
Evolutionary fingerprints of epithelial-to-mesenchymal transition
Perelli, L., Zhang, L., Mangiameli, S. M., Giannese, F., Mahadevan, K. K., Peng, F., Citron, F., Khan, H., Le, C. N., Gurreri, E., et al. (2025) · Nature · doi:10.1038/s41586-025-08671-2 · Cited by 50
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
Gómez‐España, M. A., Montés, A. F., García‐Carbonero, R., Macarulla, T. M., Maurel, J., Martín, Á., Pazo-Cid, R., Vera, R., Carrato, A., & Feliú, J. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02573-1 · Cited by 45
The Role of the Microbiome in Pancreatic Cancer
Miyabayashi, K., Ijichi, H., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184479 · Cited by 48
Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 49
Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer
Veghini, L., Pasini, D., Fang, R., Delfino, P., Filippini, D., Neander, C., Vicentini, C., Fiorini, E., Lupo, F., D’Agosto, S. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54975-8 · Cited by 46
Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer
Salinas-Miranda, E., Deniffel, D., Dong, X., Healy, G. M., Khalvati, F., O'Kane, G. M., Knox, J. J., Bathe, O. F., Baracos, V. E., Gallinger, S., et al. (2021) · European Radiology · doi:10.1007/s00330-021-07899-6 · Cited by 43
Self-citation
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Singh, H., Xiu, J., Kapner, K. S., Yuan, C., Narayan, R. R., Oberley, M. J., Farrell, A. P., Surana, R., Huffman, B. M., Perez, K. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1164 · Cited by 47
Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
Topham, J. T., Tsang, E. S., Karasinska, J. M., Metcalfe, A. L., Ali, H., Kalloger, S. E., Csizmók, V., Williamson, L., Titmuss, E., Nielsen, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33718-7 · Cited by 41
Self-citation
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer
Knox, J. J., O'Kane, G. M., King, D. A., Laheru, D. A., Habowski, A. N., Yu, K. H., Perez, K. J., Aguirre, A. J., Coyne, Z. L., Harvey, H. M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00436 · Cited by 41
Self-citation
A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models
Zhong, Z., Harmston, N., Wood, K. C., Madan, B., & Virshup, D. M. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156305 · Cited by 39
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 41
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma
Fraunhoffer, N. A., Hammel, P. R., Conroy, T., Nicolle, R., Bachet, J., Harlé, A., Rebours, V., Turpin, A., Abdelghani, M. B., Mitry, E., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.06.010 · Cited by 43
Self-citation
Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis
Pompella, L., Tirino, G., Pappalardo, A., Caterino, M., Ventriglia, A., Nacca, V., Orditura, M., Ciardiello, F., & Vita, F. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082814 · Cited by 40
Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials
Ghanem, I., Lora, D., Herradón, N., de Velasco, G., Carretero-González, A., Varas, M. Á. J., de Parga, P. V., & Feliú, J. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100485 · Cited by 39
Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models
Saiki, Y., Jiang, C., Ohmuraya, M., & Furukawa, T. (2021) · Cancers · doi:10.3390/cancers14010071 · Cited by 38
GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma
de Andrés, M. P., Jackson, R., Felipe‐Abrio, I., Zagorac, S., Pilarsky, C. P., Schlitter, A. M., de Villarreal, J. M., Jang, G. H., Costello, E., Gallinger, S., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325803 · Cited by 36
Self-citation
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial
Knox, J. J., Jang, G. H., Grant, R. C., Zhang, A. X. W., Ma, L. X., Elimova, E. C., Jang, R., Moore, M. J., Biagi, J. J., Tehfe, M. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60808-z · Cited by 39
Self-citation
Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities
Chakrabarti, S., Kamgar, M., & Mahipal, A. (2022) · Cancers · doi:10.3390/cancers14112588 · Cited by 36
Decoding the basis of histological variation in human cancer
Fujii, M., Sekine, S., & Sato, T. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00648-5 · Cited by 35
Copy Number Variations in Pancreatic Cancer: From Biological Significance to Clinical Utility
Oketch, D. J. A., Giulietti, M., & Piva, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010391 · Cited by 36
Delivery of a BET protein degrader via a CEACAM6-targeted antibody–drug conjugate inhibits tumour growth in pancreatic cancer models
Nakazawa, Y., Miyano, M., Tsukamoto, S., Kogai, H., Yamamoto, A., Iso, K., Inoue, S., Yamane, Y., Yabe, Y., Umihara, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46167-1 · Cited by 37
Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma
George, B., Kudryashova, O. M., Kravets, A. D., Thalji, S. Z., Malarkannan, S., Kurzrock, R., Chernyavskaya, E. F., Gusakova, M., Kravchenko, D., Tychinin, D. I., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.028 · Cited by 35
hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma
Perera, S., Jang, G. H., Wang, Y., Kelly, D., Allen, M. J., Zhang, A. X. W., Denroche, R. E., Dodd, A., Ramotar, S., Hutchinson, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2576 · Cited by 35
Self-citation
Moving the Needle on Precision Medicine in Pancreatic Cancer
O'Kane, G. M., & Lowery, M. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02514 · Cited by 34
Self-citation
KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Carpenter, E. S., Kadiyala, P., Elhossiny, A. M., Kemp, S. B., Li, J., Steele, N. G., Nicolle, R., Nwosu, Z. C., Freeman, J., Dai, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1421 · Cited by 32
NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4
Jain, P., Dvorkin‐Gheva, A., Mollen, E., Malbeteau, L., Xie, M. H., Jessa, F., Dhavarasa, P., Chung, S., Brown, K. R., Jang, G. H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf7114 · Cited by 33
Self-citation
Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities
Dardare, J., Witz, A., Merlin, J., Bochnakian, A., Toussaint, P., Gilson, P., & Harlé, A. (2021) · Pharmaceuticals · doi:10.3390/ph14080740 · Cited by 33
Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting
Pappalardo, A., Giunta, E. F., Tirino, G., Pompella, L., Federico, P., Daniele, B., Vita, F. D., & Petrillo, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695627 · Cited by 32
Gene Targeting in Disease Networks
Weighill, D. A., Guebila, M. B., Glass, K., Platig, J., Yeh, J. J., & Quackenbush, J. F. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.649942 · Cited by 30
Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance
Rozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 31
Epigenetic Clock and Circadian Rhythms in Stem Cell Aging and Rejuvenation
Samoilova, E. M., Викторович, Б. В., Ekusheva, E. V., Zhang, C., Troitskiy, A. V., & Baklaushev, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111050 · Cited by 32
An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer
Ruta, V., Naro, C., Pieraccioli, M., Leccese, A., Archibugi, L., Cesari, E., Panzeri, V., Allgöwer, C., Arcidiacono, P. G., Falconi, M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101411 · Cited by 29
Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives
Miyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 28
GATA6 and CK5 Stratify the Survival of Patients With Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy
Kokumai, T., Omori, Y., Ishida, M., Ohtsuka, H., Mizuma, M., Nakagawa, K., Maeda, C., Ono, Y., Mizukami, Y., Miura, S., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100102 · Cited by 28
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells
Ubhi, T., Zaslaver, O., Quaile, A. T., Plenker, D., Cao, P. M., Pham, N., Békési, A., Jang, G.-H., O'Kane, G. M., Notta, F., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00742-z · Cited by 27
Self-citation
ROR2 Regulates Cellular Plasticity in Pancreatic Neoplasia and Adenocarcinoma
Benitz, S., Steep, A., Nasser, M. M., Preall, J. B., Mahajan, U. M., McQuithey, H., Loveless, I. M., Davis, E. T., Wen, H.-J., Long, D. W., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0137 · Cited by 29
Pancreatic Cancer: Pathogenesis and Clinical Studies
Zhou, K., Liu, Y., Tang, C., & Zhu, H. (2025) · MedComm · doi:10.1002/mco2.70162 · Cited by 28
Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention
Maddipati, R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191943 · Cited by 31
Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA
Gao, C., Wisniewski, L., Liu, Y., Staal, B., Beddows, I., Plenker, D., Aldakkak, M., Hall, J., Barnett, D., Gouda, M. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2475 · Cited by 26
Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma
Ecker, B. L., Tao, A. J., Janssen, Q. P., Walch, H. S., Court, C. M., Balachandran, V. P., Crane, C. H., D'Angelica, M. I., Drebin, J. A., Kingham, T. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3089 · Cited by 26
Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma
Ma, L. X., Wang, Y., Espin‐Garcia, O., Allen, M. J., Jang, G. H., Zhang, A. X. W., Dodd, A., Ramotar, S., Hutchinson, S., Tehfe, M. A., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02214-0 · Cited by 26
Self-citation
Nab -Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer
Carrato, A., Pazo-Cid, R., Macarulla, T. M., Gallego-Plazas, J., Jiménez‐Fonseca, P., Rivera, F., Cano, M. T., Rodríguez-Garrote, M., Pericay, C., Alés, I., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2300144 · Cited by 26
MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages
Kato, H., Tateishi, K., Fujiwara, H., Nakatsuka, T., Yamamoto, K., Kudo, Y., Hayakawa, Y., Nakagawa, H., Tanaka, Y., Ijichi, H., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.12.254 · Cited by 27
Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model
Torre-Healy, L. A., Kawalerski, R. R., Oh, K., Chrastecka, L., Peng, X. L., Aguirre, A. J., Rashid, N. U., Yeh, J. J., & Moffitt, R. A. (2023) · Communications Biology · doi:10.1038/s42003-023-04461-6 · Cited by 28
Sub-Cluster Identification through Semi-Supervised Optimization of Rare-Cell Silhouettes (SCISSORS) in single-cell RNA-sequencing
Leary, J. R., Xu, Y., Morrison, A. B., Jin, C., Shen, E. C., Kuhlers, P. C., Su, Y., Rashid, N. U., Yeh, J. J., & Peng, X. L. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad449 · Cited by 28
PDAC as an immune evasive disease: can 3D model systems aid to tackle this clinical problem?
Narayanan, S., Vicent, S., & Ponz-Sarvisé, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.787249 · Cited by 24
Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer
Nimgaonkar, V. U., Krishna, V., Krishna, V., Tiu, E., Joshi, A., Vrabac, D., Bhambhvani, H. P., Smith, K., Johansen, J. S., Makawita, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101013 · Cited by 28

Authors: O’Kane, G. M., Grünwald, B. T., Jang, G.-H., Masoomian, M., Picardo, S., Grant, R. C., Denroche, R. E., Zhang, A., Wang, Y., Miller, J. K., Lam, B., Krzyzanowski, P. M., Lungu, I. M., Bartlett, J. M. S., Peralta, M., Vyas, F., Khokha, R., Biagi, J., Chadwick, D., Ramotar, S., Hutchinson, S., Dodd, A., Wilson, J. M., Notta, F., Zogopoulos, G., Gallinger, S., Knox, J. J., & Fischer, S. E.
Affiliations: 1Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Ontario Institute for Cancer Research (CA)
University Health Network (CA)
Research Institute of the McGill University Health Centre (CA)
Kingston General Hospital (CA)
ORCID: Grünwald, Barbara T.
Jang, Gun-Ho
Grant, Robert C.
Denroche, Robert E.
Zhang, Amy
Wang, Yifan
Miller, Jessica K.
Lam, Bernard
Krzyzanowski, Paul M.
Lungu, Ilinca M.
Bartlett, John M.S.
Peralta, Melanie
Vyas, Foram
Khokha, Rama
Biagi, James
Ramotar, Stephanie
Hutchinson, Shawn
Dodd, Anna
Wilson, Julie M.
Notta, Faiyaz
Zogopoulos, George
Knox, Jennifer J.
Fischer, Sandra E.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2020-03-10
Volume: 26
Issue: 18
Pages: 4901-4910
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-19-3724
OpenAlex: W3011562658
Semantic Scholar: d72ef3593540c2afcd56ffaaa1ecbdf174cca98b
Cited by: 352
References: 39
Citations by year: 2026: 54 · 2025: 58 · 2024: 58 · 2023: 60 · 2022: 48 · 2021: 56 · 2020: 16
FWCI: 16.25
Type: journal article
Language: en
Update notices: correction (2022-06-13)
Open access: green
www.research.ed.ac.uk
Licence: other-oa
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders: Princess Margaret Cancer Foundation (ALTF 116-2018, DEU 1199182 FLF-P)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords: GATA6, pancreatic ductal adenocarcinoma, basal-like subtype, classical subtype, cancer subtyping, chemoresistance, modified FOLFIRINOX, overall survival, prognostic factors, keratin 5, tumor hypoxia, COMPASS trial
MeSH terms: Irinotecan, Oxaliplatin, RNA-Seq, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Pancreatic Neoplasms, Prognosis, Prospective Studies, Multicenter Studies as Topic, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, GATA6 Transcription Factor, Response Evaluation Criteria in Solid Tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks